You are here

Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
Gothenburg, , SE-413 45 Sweden
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transplantation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Transplantation patients treated with sirolimus (Rapamune).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients must be able to give informed consent.

NCT00195195
Pfizer
Completed
Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Graft vs Host Disease, Kidney Transplantation
NCT00195273
All Genders
18+
Years
Multiple Sites
Transplant Rejection, Renal Transplantation
NCT01236378
All Genders
18+
Years
Multiple Sites
Kidney Transplantation
NCT00452361
All Genders
18+
Years
Select Cities,
Renal Transplantation
NCT00697112
All Genders
18+
Years
Multiple Sites
Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries
A Rapamune Follow-up Registry in Transplant Recipients in the Nordic Countries, "Wrap-up"
The purpose of this study is to gather information about the long-term effects and safety of treatment with Rapamune in transplant patients.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Transplantation patients treated with sirolimus.
Transplantation
Drug: Sirolimus
Transplantation patients treated with sirolimus who consent to participate in the study (register)
Other Name: Rapamune
1
Sirolimus
Intervention: Drug: Sirolimus
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
66
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Transplantation patients treated with sirolimus (Rapamune).

Exclusion Criteria:

  • Patients must be able to give informed consent.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
 
NCT00195195
0468-101157
No
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
January 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now